tert-Butyl 2-oxo-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate, 98%, 500mg

1-((2-Hydroxyethyl)amino)propan-2-ol, 95.0%, 1g

1-Bromo-4-(difluoromethoxy)naphthalene, 98%, 500mg

(R)-1-(tert-Butoxycarbonyl)-3,3-dimethyl-1,3-azasilolidine-5-carboxylic acid, 95.0%, 1g

3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde>98.0%(GC)25g

[(3-Chloro-benzyl)-cyclopropyl-amino]-acetic acid, 95.0%, 250mg

5-(2-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one hydrochloride, 95.0%, 5g

2-(4-methoxybenzyl)-1,3-dioxoisoindoline-5-carboxylic acid, 1g

2-Amino-4,6-dichlorophenol, 97.0%, 10g

Plan PLPHi S40x/0.65 objectif corrigé à l'infini IOS à contraste de phase

(S)-3-((tert-Butoxycarbonyl)amino)-3-(3-methoxyphenyl)propanoic acid, 95.0%, 5g

Cyclobutanecarbothioamide, 98%, 1g

4'-Dodecyl-[1,1'-biphenyl]-4-carbonitrile, 97%, 25g